Epirubicin is the 4′ epimer of the anthracycline antibiotic doxorubicin, and has been used
alone or in combination with other cytotoxic agents in the treatment of a variety of …

Purpose Data on optimal adjuvant therapy after complete resection of small-cell lung cancer
(SCLC) are limited, and in particular, there have been no studies evaluating the role of …

OBJECTIVE: Although resection is not the standard of care in treating small cell lung cancer,
new platinum drugs and modern staging have allowed the role of surgery to be reevaluated …

OBJECTIVE: Indications for surgical intervention for very limited small cell lung cancer have
not yet been determined. The objective of this study is to determine whether resection …

One hundred three consecutive patients undergoing 106 thoracotomies for primary lung
carcinoma were reviewed to determine factors associated with the development of …

Small-cell lung cancer (SCLC) comprises 13–20% of all lung cancers but is the fifth leading
cause of cancer death worldwide. SCLC prognosis remains poor despite improvements in …

PURPOSE To verify the superiority of irinotecan plus cisplatin over etoposide plus cisplatin
as postoperative adjuvant chemotherapy for patients with pathologic stage I-IIIA, completely …

Background. Operation with combined chemotherapy has been recently recommended for
very early stage of small cell lung cancer without lymph node metastasis. Methods. A …

Importance There is limited evidence to guide stage I to II small cell lung cancer (SCLC)
treatment. Objective To examine the characteristics and outcomes among patients with …

Background Adjuvant chemotherapy, postoperative radiation (PORT), and prophylactic
cranial irradiation (PCI) have been individually examined in limited-stage small cell lung …